Beyond Air, Inc. (XAIR): Price and Financial Metrics
XAIR Price/Volume Stats
| Current price | $0.40 | 52-week high | $3.32 |
| Prev. close | $0.41 | 52-week low | $0.36 |
| Day low | $0.39 | Volume | 114,600 |
| Day high | $0.41 | Avg. volume | 512,316 |
| 50-day MA | $0.51 | Dividend yield | N/A |
| 200-day MA | $1.27 | Market Cap | 18.31M |
XAIR Stock Price Chart Interactive Chart >
Beyond Air, Inc. (XAIR) Company Bio
Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.
Latest XAIR News From Around the Web
Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid TumorsNo dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide |
Beyond Air Independent Director Acquires 102% More StockThose following along with Beyond Air, Inc. ( NASDAQ:XAIR ) will no doubt be intrigued by the recent purchase of shares... |
Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air IncBeyond Air Inc (NASDAQ:XAIR) has witnessed a significant insider transaction on December 18, 2023, according to a recent SEC filing. |
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare ConferenceGARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic |
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond Cancer presents positive first-in-human data for intratumoral administration of ultra-high concentration nitric oxide (UNO) therapy demonstrating safety and evidence of immune system activation at the Society for Immunotherapy Conference (SITC) Submitted PMA supplement to FDA for the expansion of Lun |
XAIR Price Returns
| 1-mo | -5.24% |
| 3-mo | -68.00% |
| 6-mo | -73.33% |
| 1-year | -87.34% |
| 3-year | -96.24% |
| 5-year | -91.92% |
| YTD | -79.59% |
| 2023 | -69.80% |
| 2022 | -31.25% |
| 2021 | 79.13% |
| 2020 | 0.76% |
| 2019 | 12.47% |
Loading social stream, please wait...